Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $7.75 USD
Change Today +0.12 / 1.57%
Volume 46.9K
ORMP On Other Exchanges
As of 5:10 PM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

oramed pharmaceuticals inc (ORMP) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/13/15 - $9.84
52 Week Low
03/18/15 - $3.71
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

oramed pharmaceuticals inc (ORMP) Related Bloomberg News

View More Bloomberg News

oramed pharmaceuticals inc (ORMP) Related Businessweek News

No Related Businessweek News Found

oramed pharmaceuticals inc (ORMP) Details

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule that is in Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which is in Phase Ib clinical trials for the treatment of type 2 diabetes. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in Jerusalem, Israel.

oramed pharmaceuticals inc (ORMP) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $317.4K
Chief Financial Officer, Treasurer and Secret...
Total Annual Compensation: $127.5K
Chief Operating Officer and Vice President of...
Total Annual Compensation: $156.5K
Chief Scientific Officer and Director
Total Annual Compensation: $238.9K
Compensation as of Fiscal Year 2015.

oramed pharmaceuticals inc (ORMP) Key Developments

Oramed Completes Randomization of over 50% of Patients in Phase IIb Oral Insulin Study

Oramed Pharmaceuticals Inc. announced that 98 patients have already been enrolled in the Company's Phase IIb study of its oral insulin capsule, ORMD-0801, which represents more than 50% of the 180 patients expected to be recruited for the trial. The double-blind, randomized Phase IIb study for type 2 diabetes was initiated on June 30 and is designed to generate ample data for both efficacy and safety endpoints.

Oramed Pharmaceuticals Inc. Presents at Aegis Capital Corp 2015 Growth Conference, Oct-08-2015 01:30 PM

Oramed Pharmaceuticals Inc. Presents at Aegis Capital Corp 2015 Growth Conference, Oct-08-2015 01:30 PM. Venue: The Encore at Wynn, 3131 S Las Vegas Blvd, Las Vegas, NV 89109, United States. Speakers: Joshua Hexter, Chief Operating Officer and Vice President of Business Development.

Oramed Pharmaceuticals Inc., Annual General Meeting, Aug 11, 2015

Oramed Pharmaceuticals Inc., Annual General Meeting, Aug 11, 2015., at 11:00 US Eastern Standard Time. Location: offices of Sullivan & Worcester LLP. Agenda: To re-elect six directors of the Company to hold office until next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal; to ratify the appointment of Kesselman & Kesselman, certified public accountants in Israel, a member of PricewaterhouseCoopers International Limited, as the independent registered public accounting firm of the Company for the 2015 fiscal year; and to transact any other business as may properly come before the Annual Meeting or any adjournments thereof.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ORMP:US $7.75 USD +0.12

ORMP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abeona Therapeutics Inc $4.80 USD +0.12
View Industry Companies

Industry Analysis


Industry Average

Valuation ORMP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ORAMED PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at